Tirzepatide vs Mounjaro & Zepbound in 2026
Tirzepatide is the peptide. Mounjaro and Zepbound are Eli Lilly's branded versions. Compounded tirzepatide is a separate, individualized medicine. Here's how they differ.
Tirzepatide is one peptide with several forms. Tirzepatide is the active peptide itself. Mounjaro and Zepbound are Eli Lilly's FDA-approved branded tirzepatide products. Compounded tirzepatide is a distinct medicine that a licensed physician prescribes and a state-licensed 503A pharmacy fills for a single named patient. What separates them is access, cost, transparency, and oversight. This page walks through each form, because getting informed about your metabolic health is a smart, proactive step worth taking.
Tirzepatide is the peptide behind every version
Tirzepatide is a peptide, and it's the active molecule inside every version discussed on this page. It's a once-weekly injection that acts on two gut hormone receptors, GIP and GLP-1, which help regulate blood sugar and appetite. That dual action is why it's studied for both blood sugar control and weight management.
GLP-1 style medicines like tirzepatide and semaglutide are peptides, so they sit squarely in the category we focus on. Peptides are short chains of amino acids that signal the body to do specific things. pru is built around peptides and closely related longevity therapies, which means tirzepatide is core to what we do, not a side product. If you want the fuller peptide picture, see weight loss and metabolism.
THE SHORT VERSIONTirzepatide is the peptide. Mounjaro and Zepbound are Eli Lilly's brand names for it. Compounded tirzepatide is a separate, individualized medicine prescribed and filled for one patient.
Mounjaro and Zepbound are Eli Lilly's branded tirzepatide
Mounjaro and Zepbound are both FDA-approved branded tirzepatide made by Eli Lilly, and the difference between them is the approved use, not the molecule. Mounjaro was FDA-approved in May 2022 to improve blood sugar control in adults with type 2 diabetes. Zepbound was FDA-approved in November 2023 for chronic weight management, and in December 2024 it also gained approval for moderate-to-severe obstructive sleep apnea in adults with obesity.
Both are prefilled, fixed-dose products you get through a traditional pharmacy with a prescription. Because they're FDA-approved, they carry Eli Lilly's manufacturing, labeling, and oversight. Their list prices are set by the manufacturer, and what you actually pay depends heavily on insurance coverage and any manufacturer savings programs. That coverage question is where a lot of people get stuck.
SAME MOLECULE, DIFFERENT LABELMounjaro is the diabetes brand. Zepbound is the weight and sleep apnea brand. Both are Eli Lilly's FDA-approved tirzepatide. The brand tells you the approved use, not a different drug.
Compounded tirzepatide is a distinct, individualized medicine
Compounded tirzepatide is a separate, non-FDA-approved medicine made for one named patient by a state-licensed 503A pharmacy after a licensed physician writes the prescription. It's pharmacy-grade and not the same as Mounjaro or Zepbound. The right way to compare it to the branded products is on access, cost, and oversight.
The value of the compounded path is individualization and access. A prescriber can tailor the dose and titration to you rather than fitting you to a fixed pen. That matters most during titration, when many people move up slowly to manage side effects. For the step-by-step schedule, see our tirzepatide dosage guide.
Here's the caution that matters most. A grey-market "research-grade" vial sold online is not the same thing as pharmacy-grade medicine prescribed by a licensed doctor and filled by a licensed pharmacy. Research-grade vials aren't made for people, aren't prescribed for you, and skip the oversight that keeps you safe. The legitimate route is a physician prescription filled by a licensed 503A pharmacy. Learn more in our compounded tirzepatide overview.
Where individualized 503A compounding stands in 2026
Individualized 503A compounding is the legitimate route in 2026, but it's narrower than it used to be. When tirzepatide was in shortage, the FDA allowed broader compounding. After the FDA confirmed the tirzepatide shortage was resolved in late 2024, that enforcement flexibility ended. It ended for 503A state-licensed pharmacies on February 18, 2025, and for 503B outsourcing facilities on March 19, 2025.
So not all compounded tirzepatide is legal, and you shouldn't trust any site that says it is. What remains legitimate is individualized compounding: a licensed physician documents a clinical reason the standard FDA-approved product doesn't fit you, writes a prescription for you by name, and a state-licensed 503A pharmacy fills it for you specifically. That's the route pru uses. Mass-producing copies of an approved drug for cost or convenience is not that, and regulators have said so directly.
Tirzepatide vs Mounjaro vs Zepbound vs compounded, side by side
Here's the whole comparison in one view. Read down the columns to see how the peptide, the two Eli Lilly brands, and individualized compounded tirzepatide differ on what they are, their FDA status, who makes them, access, cost transparency, and oversight.
| Tirzepatide (the peptide) | Mounjaro | Zepbound | Compounded tirzepatide (pru) | |
|---|---|---|---|---|
| What it is | The active peptide molecule | Branded tirzepatide for diabetes | Branded tirzepatide for weight and sleep apnea | Individualized, pharmacy-grade tirzepatide for one patient |
| FDA status | An ingredient, not a finished product | FDA-approved (2022) | FDA-approved (2023) | Individually compounded via 503A |
| Who makes it | Various suppliers | Eli Lilly | Eli Lilly | A state-licensed 503A pharmacy |
| Access | Not sold as a finished medicine | Prescription, traditional pharmacy | Prescription, traditional pharmacy | Physician prescription, filled and shipped by a 503A pharmacy |
| Cost & transparency | Not applicable | Manufacturer-set; varies with insurance | Manufacturer-set; varies with insurance | Sold at cost, itemized, no markup on the peptide |
| Oversight | Not applicable | FDA-regulated manufacturing | FDA-regulated manufacturing | Licensed physician plus a state-licensed 503A pharmacy |
| Individualization | None | Fixed doses | Fixed doses | Dose and titration tailored to you |
If insurance covers a branded product for you, that's a strong option. If access, cost clarity, and a tailored dose matter more, the individualized compounded route through a physician and a 503A pharmacy is worth understanding. For a related comparison, see semaglutide vs tirzepatide.

What tirzepatide costs, and how access differs
The branded products carry a high list price. Eli Lilly's Mounjaro and Zepbound run roughly $1,000 or more per month at list, before insurance. What you actually pay depends heavily on your coverage and any manufacturer savings programs. If your plan covers a branded product, that discount can be large. If it doesn't, that list price is the wall a lot of people hit.
pru works the other way around. A flat membership of about $50 a month, billed annually, funds the platform, and the peptide itself is priced at cost with no markup on the medicine. The fill, supplies, shipping, and consult are itemized so you can see what you're paying for. A branded pen depends on your insurance; the individualized compounded route through a physician and a 503A pharmacy is priced at cost and shown to you. See exactly how that works on our pricing page.
THE COST PICTUREBranded tirzepatide lists around $1,000 or more a month before insurance. pru charges a flat membership and offers the peptide at cost, itemized, with no markup on the medicine. One depends on coverage. The other is priced openly.
What the trials of the branded FDA-approved product show
This is background about Eli Lilly's FDA-approved branded product, not a claim about compounded tirzepatide or about pru. In Eli Lilly's SURMOUNT-1 trial of Zepbound, adults with obesity or overweight lost about 15% of body weight at the 5 mg dose, about 19.5% at 10 mg, and about 20.9% at 15 mg over 72 weeks. Those figures describe the branded, FDA-approved product as it was studied.
THESE ARE THE BRANDED DRUG'S RESULTSThe SURMOUNT-1 numbers above are results for Eli Lilly's branded Zepbound in a clinical trial. They are not a promise about a compounded product, and they are not a result we attribute to pru.
What happens if you stop taking it
Tirzepatide is generally studied as an ongoing treatment, not a short course, and stopping tends to reverse the effect. In Eli Lilly's SURMOUNT-4 trial of the branded, FDA-approved product, participants who stopped tirzepatide regained a meaningful share of the weight they had lost, while those who stayed on it kept losing or held steady. That is background about the branded drug as studied, not a claim about compounded tirzepatide or about pru.
The practical takeaway is that this is a decision to make with a prescriber, thinking about the long term rather than a quick fix. Your physician sets the plan, including what maintenance looks like and how any change in dose is handled. That's part of why the individualized, physician-guided path matters.
How pru handles tirzepatide
With pru, tirzepatide runs through a clean, individualized path built around licensed people, not a grey-market vial. A licensed physician reviews your intake and, if appropriate, writes your prescription and sets your titration. A state-licensed, FDA-regulated 503A pharmacy fills it for you by name and ships it to your door.
The pricing is the part people remember. A flat membership of about $50 a month, billed annually, funds the platform. Every peptide is then priced at cost, itemized so you can see the pharmacy fill, supplies, shipping, and consult. There's no markup on the medicine. See exactly how that works on our pricing page.
That's the pru idea in one line: peptides made simple, for everyone, with easy access, complete support, and transparent at-cost pricing. Being proactive about your metabolic health is a smart, responsible choice, and pru exists to make that choice the accessible one, pairing licensed physicians and pharmacy-grade medicine with at-cost pricing. Take the next step when you're ready: start with tirzepatide, or if you're not sure where to buy the individualized route safely, read where to buy compounded tirzepatide.

Related reading
- Semaglutide vs tirzepatide
- Semaglutide vs Ozempic and Wegovy
- Compounded tirzepatide, explained
- Tirzepatide dosage and titration
- see it on pru
Common questions
Sources & further reading
- U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection. fda.gov.
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. fda.gov.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information. accessdata.fda.gov.
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound). fda.gov.
- National Center for Biotechnology Information. Tirzepatide, StatPearls. ncbi.nlm.nih.gov.
- joinpru.com. pru pricing and compounded tirzepatide. joinpru.com.
- Eli Lilly and Company. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
- Eli Lilly and Company. SURMOUNT-4: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA, 2024.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information and clinical studies. accessdata.fda.gov.
- In U.S., GLP-1 Usage Reaches New High (Gallup, 2025): about 1 in 8 U.S. adults have used a GLP-1 medicine.